Stoke Therapeutics, Inc.
STOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $36,555 | $8,780 | $12,405 | $0 |
| % Growth | 316.3% | -29.2% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $36,555 | $8,780 | $12,405 | $0 |
| % Margin | 100% | 100% | 100% | – |
| R&D Expenses | $89,133 | $82,231 | $77,837 | $54,168 |
| G&A Expenses | $48,794 | $41,322 | $38,924 | $31,897 |
| SG&A Expenses | $48,794 | $41,322 | $38,924 | $31,897 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $137,927 | $123,553 | $116,761 | $86,065 |
| Operating Income | -$101,372 | -$114,773 | -$104,356 | -$86,065 |
| % Margin | -277.3% | -1,307.2% | -841.2% | – |
| Other Income/Exp. Net | $12,391 | $10,074 | $3,289 | $260 |
| Pre-Tax Income | -$88,981 | -$104,699 | -$101,067 | -$85,805 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$88,981 | -$104,699 | -$101,067 | -$85,805 |
| % Margin | -243.4% | -1,192.5% | -814.7% | – |
| EPS | -1.65 | -2.38 | -2.6 | -2.34 |
| % Growth | 30.7% | 8.5% | -11.1% | – |
| EPS Diluted | -1.65 | -2.38 | -2.6 | -2.34 |
| Weighted Avg Shares Out | 54,009 | 43,995 | 38,897 | 36,739 |
| Weighted Avg Shares Out Dil | 54,009 | 43,995 | 38,897 | 36,739 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $120 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,177 | $2,469 | $1,546 | $974 |
| EBITDA | -$99,195 | -$112,304 | -$102,810 | -$85,091 |
| % Margin | -271.4% | -1,279.1% | -828.8% | – |